R 305
2015 -- S 0934
Enacted 05/20/2015

S E N A T E   R E S O L U T I O N

Introduced By: Senators Coyne, Lombardi, Morgan, Ottiano, and Archambault
Date Introduced: May 19, 2015

     WHEREAS, Cystic Fibrosis, commonly referred to as "CF", is a genetic disease affecting
approximately 30,000 children and adults in the United States and nearly 70,000 children and
adults worldwide, 99 of whom live in this state; and
     WHEREAS, A defective gene causes the body to produce an abnormally thick, sticky
mucus that clogs the lungs, and these secretions produce life-threatening lung infections and
obstruct the pancreas, preventing digestive enzymes from reaching the intestines to help break
down and absorb food; and
     WHEREAS, More than 10 million Americans are symptomless carriers of the defective
CF gene, and CF occurs in approximately one of every 3,500 live births in the United States; and
     WHEREAS, The median age of survival for a person with CF is 41.1 years; and
     WHEREAS, With advances in the treatment of CF, the number of adults with this disease
has steadily grown and approximately 1,000 new cases of this disease are diagnosed each year;
     WHEREAS, Nearly 50 percent of the CF population is 18 years of age and older and
have a variety of symptoms attributed to the more than 1,800 mutations of the CF gene; and
     WHEREAS, Infant blood screening to detect genetic defects is the most reliable and least
costly method to identify persons likely to have CF; and
     WHEREAS, The treatment of CF depends on the stage of the disease and the organs
involved. Early diagnosis of CF permits early treatment and enhances quality of life and
longevity; and
     WHEREAS, Clearing mucus from the lungs is an important part of the daily CF
treatment regimen. Additional types of treatments include inhaled antibiotics and pancreatic
enzymes, among others; and
     WHEREAS, In this state, the Brown University Medical School/Rhode Island Hospital
Cystic Fibrosis Center is a world-class treatment center which specializes in the diagnosis and
care of persons with CF; and
     WHEREAS, A critical component in treating patients with CF includes access to
innovative medicines, which can play a crucial role in the lives of patients with CF; and
     WHEREAS, Improving the length and quality of life for people with CF starts with
awareness; now, therefore be it
     RESOLVED, That this Senate of the State of Rhode Island and Providence Plantations
hereby designates the Month of May 2015, as "Cystic Fibrosis Awareness Month" in the State of
Rhode Island; and be it further
     RESOLVED, That the Secretary of State be and hereby is authorized and directed to
transmit a duly certified copy of this resolution to Pamela Spitzer, Massachusetts/Rhode Island
Executive Director, Cystic Fibrosis Foundation.